Literature DB >> 16425302

Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.

Yoon-Ah Park1, Seung-Kook Sohn, Jinsil Seong, Seung-Hyuk Baik, Kang-Young Lee, Nam-Kyu Kim, Chang-Whan Cho.   

Abstract

BACKGROUND AND OBJECTIVES: Recent data suggest that good responders to preoperative chemoradiation (CRT) have a favorable prognosis in rectal cancer patients. The aim of this study was to investigate the predictive value of serum carcinoembryonic antigen (CEA) levels for the tumor response to preoperative CRT in rectal cancer patients.
METHODS: The study comprised 141 rectal adenocarcinoma patients who underwent preoperative radiotherapy with 5-fluorouracil (FU) based chemotherapy, followed by radical surgery. The staging workup was consisted of endorectal ultrasound, abdominopelvic computed tomography scan, or magnetic resonance imaging. The outcome parameters were cancer-specific survival and disease-free survival. Pre-CRT clinicopathologic features, including age, gender, location of the tumor, clinical tumor (cT) classification, clinical nodal (cN) classification, and serum CEA levels were investigated as possible predictors for the response to preoperative CRT.
RESULTS: Pathologic complete or near complete responses (good responders, GR) occurred in 26 (19%) patients, while partial or no response (poor responders, PR) occurred in the remaining 115 (81%) patients. GR showed better cancer-specific survival (P = 0.028) and disease-free survival rates (P = 0.011) than PR. Univariate analysis revealed that positive cN and elevated (>5 ng/ml) pre-CRT serum CEA levels are associated with poor tumor response to preoperative CRT. Using logistic regression analysis, elevated pre-CRT serum CEA levels were the only significant predictor for the poor response to CRT (Odd ratio = 2.876, 95% confidence interval = 1.04-7.46, P = 0.041).
CONCLUSIONS: Our data suggest that elevated pre-CRT serum CEA levels are associated with poor tumor response to CRT. Therefore, pre-CRT serum CEA levels provide useful information about tumor response to preoperative CRT in rectal cancer patients. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16425302     DOI: 10.1002/jso.20320

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  36 in total

1.  Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy.

Authors:  Jong Wan Kim; Hyun Chul Kim; Ji Won Park; Sung Chan Park; Dae Kyung Sohn; Hyo Seong Choi; Dae Yong Kim; Hee Jin Chang; Ji Yeon Baek; Sun Young Kim; Seok Ki Kim; Jae Hwan Oh
Journal:  Int J Colorectal Dis       Date:  2013-02-13       Impact factor: 2.571

2.  Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: Prognostic factors.

Authors:  Sofia Conde; Margarida Borrego; Tânia Teixeira; Rubina Teixeira; Anabela Sá; Paula Soares
Journal:  Rep Pract Oncol Radiother       Date:  2012-08-21

3.  Normalization of CEA Levels Post-Neoadjuvant Therapy is a Strong Predictor of Pathologic Complete Response in Rectal Cancer.

Authors:  Ariella Kleiman; Ahmed Al-Khamis; Ali Farsi; Abbas Kezouh; Te Vuong; Philip H Gordon; Carol-Ann Vasilevsky; Nancy Morin; Julio Faria; Gabriela Ghitulescu; Marylise Boutros
Journal:  J Gastrointest Surg       Date:  2015-04-10       Impact factor: 3.452

4.  Postoperative carcinoembryonic antigen level has a prognostic value for distant metastasis and survival in rectal cancer patients who receive preoperative chemoradiotherapy and curative surgery: a retrospective multi-institutional analysis.

Authors:  Songmi Jeong; Taek Keun Nam; Jae Uk Jeong; Sung Hwan Kim; Kyubo Kim; Hong Seok Jang; Bae Kwon Jeong; Jong Hoon Lee
Journal:  Clin Exp Metastasis       Date:  2016-08-23       Impact factor: 5.150

5.  Predicting response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer with serum biomarkers.

Authors:  T L Clarke; D A White; M E Osborne; A M Shaw; N J Smart; I R Daniels
Journal:  Ann R Coll Surg Engl       Date:  2017-05       Impact factor: 1.891

6.  Relations of Changes in Serum Carcinoembryonic Antigen Levels before and after Neoadjuvant Chemoradiotherapy and after Surgery to Histologic Response and Outcomes in Patients with Locally Advanced Rectal Cancer.

Authors:  Gota Saito; Sotaro Sadahiro; Takashi Ogimi; Hiroshi Miyakita; Kazutake Okada; Akira Tanaka; Toshiyuki Suzuki
Journal:  Oncology       Date:  2017-12-22       Impact factor: 2.935

7.  Can serum dynamics of carcinoembryonic antigen level during neoadjuvant chemoradiotherapy in rectal cancer predict tumor response and recurrence? A multi-institutional retrospective study.

Authors:  Mi Joo Chung; Taek Keun Nam; Jae Uk Jeong; Sung Hwan Kim; Kyubo Kim; Hong Seok Jang; Bae Kwon Jeong; Jong Hoon Lee
Journal:  Int J Colorectal Dis       Date:  2016-07-28       Impact factor: 2.571

8.  Preoperative elevation of carcinoembryonic antigen predicts poor tumor response and frequent distant recurrence for patients with rectal cancer who receive preoperative chemoradiotherapy and total mesorectal excision: a multi-institutional analysis in an Asian population.

Authors:  Jong Hoon Lee; Sung Hwan Kim; Hong Seok Jang; Hyuk Jun Chung; Seong Taek Oh; Doo Seok Lee; Jun-Gi Kim
Journal:  Int J Colorectal Dis       Date:  2012-12-04       Impact factor: 2.571

9.  Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

Authors:  Zachary S Morris; Sandeep Saha; William J Magnuson; Brett A Morris; Jenna F Borkenhagen; Alisa Ching; Gayle Hirose; Vanesa McMurry; David M Francis; Paul M Harari; Rick Chappell; Stuart Tsuji; Mark A Ritter
Journal:  Cancer       Date:  2016-05-20       Impact factor: 6.860

Review 10.  Pre-treatment carcinoembryonic antigen and outcome of patients with rectal cancer receiving neo-adjuvant chemo-radiation and surgical resection: a systematic review and meta-analysis.

Authors:  Giuseppe Colloca; Antonella Venturino; Pasquale Vitucci
Journal:  Med Oncol       Date:  2017-09-07       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.